A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Renata Belfort, Stephen A. Harrison, Kenneth Brown et al. · New England Journal of Medicine · 2006
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Cited by 1,829 works. doi:10.1056/nejmoa060326 Open-access PDF
Authors
- Renata Belfort
- Stephen A. Harrison
- Kenneth Brown
- Celia Darland
- Joan Finch
- Jean Hardies
- Bogdan Balas
- Amalia Gastaldelli
- Fermin O. Tio
- Joseph P. Pulcini
- Rachele Berria
- Jennie Z. Ma
- Sunil Kumar Dwivedi
- Russell D. Havranek
- Chris Fincke
- Ralph Anthony DeFronzo
- George A. Bannayan
- Steven Schenker
- Kenneth J. Cusi
References
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.
- Role of AMP-activated protein kinase in mechanism of metformin action
- Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
- Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
- Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
- Molecular mediators of hepatic steatosis and liver injury
- The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways
- Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand Rosiglitazone